If COAST is a complete failure, I would expect SP maybe to hit 50c or so as the market will still have some hope that SHORE reach statistical significance (in reality COAST and SHORE will both print similar results given there is not much difference between eylea and lucentis in the real world).
The market is mispricing the COAST risk because of two primary reasons in my opinion:
1. No direct previous head to head data on how sozinibercept performs with eylea.
2. No data on how sozinibercept performs at 52w
The company released that comment on masked data performance at 52w to temper market worries re: point 2 but obviously it has not been effective as we are still at $1 SP
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable